Ratios

		vs industry	vs history
P/B	2.30	UPI's P/B is ranked lower than 67% of the 165 Companies in the Global Medical Devices industry. ( Industry Median: 1.99 vs. UPI: 2.30 )	UPI' s 10-Year P/B Range Min: 0.44   Max: 10.06 Current: 2.3 0.44 10.06
P/S	1.94	UPI's P/S is ranked lower than 64% of the 165 Companies in the Global Medical Devices industry. ( Industry Median: 1.70 vs. UPI: 1.94 )	UPI' s 10-Year P/S Range Min: 0.38   Max: 11.49 Current: 1.94 0.38 11.49
EV-to-EBIT	-10.89	UPI's EV-to-EBIT is ranked higher than 52% of the 165 Companies in the Global Medical Devices industry. ( Industry Median: 16.25 vs. UPI: -10.89 )	UPI' s 10-Year EV-to-EBIT Range Min: 103   Max: 355.9 Current: -10.89 103 355.9

Valuation & Return

		vs industry	vs history
Price/Net Cash	5	UPI's Price/Net Cash is ranked higher than 84% of the 165 Companies in the Global Medical Devices industry. ( Industry Median: 12.00 vs. UPI: 5 )	UPI' s 10-Year Price/Net Cash Range Min: 2.1   Max: 20.4 Current: 5 2.1 20.4
Price/Net Current Asset Value	15.3	UPI's Price/Net Current Asset Value is ranked higher than 87% of the 165 Companies in the Global Medical Devices industry. ( Industry Median: 8.90 vs. UPI: 15.3 )	UPI' s 10-Year Price/Net Current Asset Value Range Min: 5.5   Max: 50.8 Current: 15.3 5.5 50.8
Price/Tangible Book	2.4	UPI's Price/Tangible Book is ranked higher than 70% of the 165 Companies in the Global Medical Devices industry. ( Industry Median: 3.80 vs. UPI: 2.4 )	UPI' s 10-Year Price/Tangible Book Range Min: 1.2   Max: 6.7 Current: 2.4 1.2 6.7
Price/Median PS Value	0.8	UPI's Price/Median PS Value is ranked higher than 82% of the 165 Companies in the Global Medical Devices industry. ( Industry Median: 0.80 vs. UPI: 0.8 )	UPI' s 10-Year Price/Median PS Value Range Min: 0.3   Max: 3.2 Current: 0.8 0.3 3.2
Forward Rate of Return (Yacktman)	-12.94	UPI's Forward Rate of Return (Yacktman) is ranked higher than 63% of the 165 Companies in the Global Medical Devices industry. ( Industry Median: 3.03 vs. UPI: -12.94 )	UPI' s 10-Year Forward Rate of Return (Yacktman) Range Min: 0.1   Max: 37.4 Current: -12.94 0.1 37.4

Business Description

Uroplasty, Inc. was incorporated in January 1992 as a Minnesota Corporation and a wholly owned subsidiary of its original parent. In February 1995, it became a stand-alone, privately held Company to a Plan of Reorganization confirmed by the U.S. Bankruptcy Court. It is a medical device Company that develops, manufactures and markets innovative, proprietary products for the treatment of voiding dysfunctions. The Company focuses on two products: Urgent PC system, which is the only FDA-approved minimally invasive, office-based neurostimulation therapy for the treatment of urinary urgency, urinary frequency, and urge incontinence - symptoms often associated with overactive bladder (OAB); and Macroplastique, a urethral bulking agent for the treatment of adult female stress urinary incontinence mainly due to intrinsic sphincter deficiency (ISD). The physicians prefer its products because they offer an effective therapy for the patient, could be administered in office-based settings and, to the extent reimbursement are in place, provide the physicians a new profitable recurring revenue stream. The patients prefer its products because they are minimally invasive treatment alternatives and neither have the side effects associated with pharmaceutical treatment options nor the morbidity associated with surgery. The Company has a U.S. Food and Drug Administration (FDA)-qualified manufacturing facility in Minnetonka, Minnesota. The Company manufactures all of its tissue bulking products at its Minnesota facility. It is focus the Company's sales and marketing efforts mainly on urologists, urogynecologists and gynecologists with office-based and outpatient surgery-based patient volume. The market for voiding dysfunction products is intensely competitive. Competitors offer management and curative treatments, including neurostimulation devices, tissue bulking agents and urethral sling products. The Company has registered Uroplasty, Macroplastique, VOX, PTQ and Bioplastique as trademarks with the U.S. Patent and Trademark Office and throughout the European Union. The testing, manufacturing, promotion, marketing and distribution of its products in the United States, Europe and other parts of the world are subject to regulation by numerous governmental authorities, including the FDA, the European Union and other analogous agencies.
Company Website
SEC Reports

Industry:	Medical Devices
Compare:	MDT, SYK, SMA, ZMH, STJ

» More Articles for UPI

Headlines

Articles On GuruFocus.com

Uroplasty Inc Reports Operating Results (10-K/A) Feb 22 2011

Uroplasty Inc (UPI) COO Susan Hartjes Holman sells 12,000 Shares Feb 04 2011

Uroplasty Inc Reports Operating Results (10-Q) Jan 27 2011

Uroplasty Inc Reports Operating Results (10-Q) Oct 27 2010

Uroplasty Inc Reports Operating Results (10-K/A) Jun 18 2010

Uroplasty Inc Reports Operating Results (10-Q) Feb 01 2010

Uroplasty Inc Reports Operating Results (10-Q) Nov 02 2009

Uroplasty Inc Reports Operating Results (10-Q) Aug 04 2009

Uroplasty Inc Reports Operating Results (10-Q) Feb 04 2009

Personalized Checklist